Inozyme Pharma Stock Price To Sales
| INZYDelisted Stock | USD 4.00 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Inozyme Pharma's long-term financial health and intrinsic value.
Inozyme |
Inozyme Pharma Company Price To Sales Analysis
Inozyme Pharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Inozyme Pharma has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Inozyme Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in price to sales category among its peers.
Inozyme Fundamentals
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 220.43 M | ||||
| Shares Outstanding | 64.56 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 94.29 % | ||||
| Number Of Shares Shorted | 3.38 M | ||||
| Price To Book | 8.12 X | ||||
| EBITDA | (104.03 M) | ||||
| Net Income | (102.02 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.87 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.54 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (91.91 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (1.68) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 67 | ||||
| Beta | 2.29 | ||||
| Market Capitalization | 258.25 M | ||||
| Total Asset | 123.18 M | ||||
| Retained Earnings | (387.95 M) | ||||
| Working Capital | 86.78 M | ||||
| Net Asset | 123.18 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Inozyme Stock
If you are still planning to invest in Inozyme Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inozyme Pharma's history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |